These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27143594)

  • 1. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia.
    Kasliwal RR; Bansal M; Gupta R; Shah S; Dani S; Oomman A; Pai V; Prasad GM; Singhvi S; Patel J; Sivam S; Trehan N
    Nutrition; 2016; 32(7-8):767-76. PubMed ID: 27143594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial.
    Becker DJ; French B; Morris PB; Silvent E; Gordon RY
    Am Heart J; 2013 Jul; 166(1):187-96. PubMed ID: 23816039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia.
    Yang NC; Chou CW; Chen CY; Hwang KL; Yang YC
    Asia Pac J Clin Nutr; 2009; 18(3):310-7. PubMed ID: 19786378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.
    Ruscica M; Pavanello C; Gandini S; Macchi C; Botta M; Dall'Orto D; Del Puppo M; Bertolotti M; Bosisio R; Mombelli G; Sirtori CR; Calabresi L; Magni P
    Nutr J; 2019 Feb; 18(1):13. PubMed ID: 30795775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.
    Verhoeven V; Lopez Hartmann M; Remmen R; Wens J; Apers S; Van Royen P
    BMC Complement Altern Med; 2013 Jul; 13():178. PubMed ID: 23866314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Effects of Cucumis sativus Seed Extract on Serum Lipids in Adult Hyperlipidemic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Soltani R; Hashemi M; Farazmand A; Asghari G; Heshmat-Ghahdarijani K; Kharazmkia A; Ghanadian SM
    J Food Sci; 2017 Jan; 82(1):214-218. PubMed ID: 27886382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.
    Becker DJ; Gordon RY; Halbert SC; French B; Morris PB; Rader DJ
    Ann Intern Med; 2009 Jun; 150(12):830-9, W147-9. PubMed ID: 19528562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Gerards MC; Terlou RJ; Yu H; Koks CH; Gerdes VE
    Atherosclerosis; 2015 Jun; 240(2):415-23. PubMed ID: 25897793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement.
    Heber D; Yip I; Ashley JM; Elashoff DA; Elashoff RM; Go VL
    Am J Clin Nutr; 1999 Feb; 69(2):231-6. PubMed ID: 9989685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention.
    Heinz T; Schuchardt JP; Möller K; Hadji P; Hahn A
    Nutr Res; 2016 Oct; 36(10):1162-1170. PubMed ID: 27865358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
    Cicero AF; Derosa G; Pisciotta L; Barbagallo C;
    J Med Food; 2015 Nov; 18(11):1270-3. PubMed ID: 26274827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial.
    Verhoeven V; Van der Auwera A; Van Gaal L; Remmen R; Apers S; Stalpaert M; Wens J; Hermans N
    BMC Complement Altern Med; 2015 Mar; 15():52. PubMed ID: 25879228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.